Skip to content

WellSpan-THRIVE Cancer QOL Study

WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07433660
Acronym
THRIVE
Enrollment
1000
Registered
2026-02-25
Start date
2026-02-01
Completion date
2031-12-01
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Abdomen, Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative, Cancer (Advanced Stage), Cancer - Ovarian, Cancer (Solid Tumors), Cancer (With or Without Metastasis)

Keywords

Cancer, Quality of Life, QOL, Registry, Patient

Brief summary

Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences. This study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.

Detailed description

Cancer is a leading cause of morbidity and mortality worldwide. With more than 10 million deaths in 2020, it is imposing a significant burden on individuals, families, and healthcare systems. Cancer treatment often involves a combination of therapies, such as surgery, chemotherapy, and radiation therapy, which can lead to a range of physical and psychological side effects. Side effects such as fatigue, pain, and neuropathy can greatly affect a cancer patient's quality of life, impacting their ability to function, their emotional health, and their social relationships. Research into cancer-related quality of life (QOL) has become increasingly important, as it helps us understand how cancer impacts every part of a patient's life, not just survival. Involving patients in their own care is a powerful way to boost engagement and gain deeper insight into the factors that influence quality of life during the cancer journey. Many studies have looked at what affects quality of life (QOL) in cancer patients. Factors such as age, stage of disease, type of cancer, education, income, and treatment side effects all play a role. For example, older age, advanced cancer, and certain types like lung or pancreatic cancer can lower QOL, while treatment side effects such as fatigue, pain, and neuropathy can make it harder for patients to do daily activities and enjoy life. Research has made important progress in understanding how physical, emotional, and social issues impact well-being, but challenges remain in fully capturing all the factors that influence QOL for people living with cancer. The goal is to bridge this gap by developing and implementing a patient-centered quality of life (QOL) survey tailored specifically for cancer patients and aims to capture a more accurate and comprehensive picture of the factors that affect their quality of life.

Interventions

None listed

Sponsors

WellSpan Health
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years and above * Primary cancer diagnosis (newly diagnosed within the past 6 months) * Able to sign informed consent.

Exclusion criteria

* Patients with age\<18 years, * Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies. * Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire. * Patients with life expectancy of \<90 days, in the opinion of treating investigator.

Design outcomes

Primary

MeasureTime frameDescription
Quality of Life Differences based on Race or Ethnicity or GenderBaseline, 6-12-18-24 monthsQuality of Life Differences based on Race or Ethnicity or Gender based on Quality-of-life questionnaire. We will look for changes in each question on Quality-of-life from baseline to 6-12-18-24 months.

Countries

United States

Contacts

CONTACTJoan K Moore, MSN, RN, OCN, CCRP
jmoore@wellspan.org717-741-8124
CONTACTRahul Kashyap, MBBS, MBA, FCCM
rkashyap@wellspan.org717-851-4611
PRINCIPAL_INVESTIGATORNavesh Sharma, DO, PhD, FACRO

WellSpan Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026